Jason P Simon

US Patent:

8535887, Sep 17, 2013

Filed:

May 21, 2010

Appl. No.:

12/785060

Inventors:

Arthur Bertelsen - Ridgewood NJ, US
Jacques Fellay - Durham NC, US
Dongliang Ge - Raleigh NC, US
David B. Goldstein - Durham NC, US
John G. McHutchison - Chapel Hill NC, US
Ping Qiu - Edison NJ, US
Kevin Shianna - Durham NC, US
Jason S. Simon - Westfield NJ, US
Alexander J. Thompson - Durham NJ, US
Thomas Urban - Durham NC, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C12Q 1/70
C12Q 1/68

US Classification:

435 611, 435 5, 435 61, 435 612

Abstract:

The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-α). These IFN-α response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-α pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-α, and in methods for selecting the most appropriate therapy for such patients.

US Patent:

20180209980, Jul 26, 2018

Filed:

Mar 23, 2018

Appl. No.:

15/934242

Inventors:

- Tokyo, JP
Tadashi Kadowaki - Tsukuba, JP
Junji Matsui - Tsukuba, JP
Jason S. Simon - Woodcliff Lake NJ, US
Lucy Xu - Woodcliff Lake NJ, US

Assignee:

Eisai R&D Management Co., Ltd. - Tokyo

International Classification:

G01N 33/574
C12Q 1/6886
A61K 31/47

Abstract:

Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.

US Patent:

20140187577, Jul 3, 2014

Filed:

May 31, 2012

Appl. No.:

14/122339

Inventors:

Yasuhiro Funahashi - Tsukuba-shi, JP
Tadashi Kadowaki - Tsukuba-shi, JP
Junji Matsui - Tsukuba-shi, JP
Jason S. Simon - Woodcliff Lake NJ, US
Lucy Xu - Woodcliff Lake NJ, US

Assignee:

EISAI R&D MANAGEMENT CO., LTD. - Tokyo

International Classification:

G01N 33/574
A61K 31/47
C12Q 1/68

US Classification:

514312, 435 611, 435 792

Abstract:

Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.